» Authors » D H Vu

D H Vu

Explore the profile of D H Vu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 225
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis . 2023 Jun; 27(7):506-519. PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
2.
Alffenaar J, Stocker S, Davies Forsman L, Garcia-Prats A, Heysell S, Aarnoutse R, et al.
Int J Tuberc Lung Dis . 2022 Jun; 26(6):483-499. PMID: 35650702
Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance...
3.
Nguyen T, Cao T, Akkerman O, Tiberi S, Vu D, Alffenaar J
Expert Rev Clin Pharmacol . 2016 Jun; 9(8):1025-37. PMID: 27322153
Introduction: Few innovative anti-microbial products have been brought to market in recent years to combat the global multidrug resistant-tuberculosis (MDR-TB) epidemic. Bedaquiline, a novel oral diarylquinoline, was approved by the...
4.
Vu D, Koster R, Bolhuis M, Greijdanus B, Altena R, Nguyen D, et al.
Talanta . 2014 Mar; 121:9-17. PMID: 24607103
Introduction: Rifampicin (RIF) and clarithromycin (CLR) are common drugs for the treatment of infections like Mycobacterium tuberculosis and Mycobacterium ulcerans. Treatment for these diseases are long-term and the individual pharmacokinetic...
5.
Vu D, Koster R, Wessels A, Greijdanus B, Alffenaar J, Uges D
J Chromatogr B Analyt Technol Biomed Life Sci . 2013 Jan; 917-918:1-4. PMID: 23353809
Clarithromycin and rifampicin are used for the treatment of Mycobacteria. Pharmacokinetic drug interaction is possibly due to the influence of the two drugs on the liver enzymes. Using a Hypurity...
6.
Vu D, van Rein N, Cobelens F, Nguyen T, Le V, Brouwers J
Int J Tuberc Lung Dis . 2012 Nov; 16(12):1625-9. PMID: 23131260
Settings: Private pharmacies in Hanoi, Viet Nam. Objectives: To explore the response of health care providers (HCPs) in private pharmacies to suspected tuberculosis (TB) patients. Methods: A simulated patient method...
7.
Vu D, Bolhuis M, Koster R, Greijdanus B, de Lange W, van Altena R, et al.
Antimicrob Agents Chemother . 2012 Aug; 56(11):5758-63. PMID: 22926568
Linezolid is a promising antimicrobial agent for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its use is limited by toxicity. Therapeutic drug monitoring (TDM) may help to minimize toxicity while...
8.
Vu D, Alffenaar J, Edelbroek P, Brouwers J, Uges D
Curr Pharm Des . 2011 Aug; 17(27):2931-9. PMID: 21834763
Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by the emergence of multidrug resistance and TB-HIV coinfection....
9.
Vu D, Koster R, Alffenaar J, Brouwers J, Uges D
J Chromatogr B Analyt Technol Biomed Life Sci . 2011 Apr; 879(15-16):1063-70. PMID: 21459055
Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, therapeutic drug monitoring...
10.
Harris R, Vu D, Sonnabend D, Goldberg J, Walsh W
J Shoulder Elbow Surg . 2001 Dec; 10(6):585-8. PMID: 11743540
The coracoclavicular ligaments vary widely in morphology and anatomic descriptions. Few authors have adequately described the coracoclavicular ligaments' anatomy, and a number of discrepancies exist in the anatomy literature. This...